Metabolics biotech secures humble Series A from big-name investors
Lipidio Pharmaceuticals launched right before Covid-19 took the world by storm, initially focusing on metabolic indications such as NASH, Prader-Willi Syndrome and anti-psychotic drug-induced weight gain.
More than 2.5 years later, the biotech has added dermatology to that list and secured some of the industry’s most well-known investors for a Series A extension round.
Lipidio announced on Thursday morning that it has raised more than $20 million. It also secured three former biotech chiefs as new investors: Tanox founder and ex-CEO Nancy Chang, Allergan veteran Brent Saunders and founding Alnylam CEO John Maraganore, who seems to be everywhere these days after leaving his post at the RNAi giant.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.